Monopar Therapeutics

Monopar Therapeutics Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 18% premium over our quantitative fair value estimate of $70.88 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's lack of profitability decreases our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -2.0%, which lies in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

On a different note, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio, for example, ranks in the top 1% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.